Harvard Bioscience, Inc. (HBIO) Balance Sheet
HBIO balance sheet, 2025
December 31, 2025 · U.S. dollars$80.1M assets = $66.3M liabilities + $13.7M equity
Both columns are drawn to the same scale: what HBIO owns equals what it owes plus shareholders’ equity. Hover a block for its value.
HBIO financial health
Descriptive bands, not a rating. Fiscal 2025.
HBIO balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $107.8M2016 | $80.1M2025 | −3.2%/yr | |
| Total liabilities | $35.6M2016 | $66.3M2025 | +7.2%/yr | |
| Shareholders’ equity | $72.2M2016 | $13.7M2025 | −16.8%/yr | |
| Cash & short-term investments | $5.6M2016 | $8.6M2025 | +4.9%/yr | |
| Total debt | $13.7M2016 | $44.3M2025 | +13.9%/yr | |
| Net cash (debt) | −$8.2M2016 | −$35.7M2025 | −$27.5M | |
| Working capital | $30.9M2016 | $26.3M2025 | −$4.6M | |
| Book value per share | $21.102016 | $3.092025 | −19.2%/yr | |
| Current ratio | 3.112016 | 2.202025 | −0.92 | |
| Debt / equity | 0.192016 | 3.222025 | +3.03 | |
| Shares outstanding | 3.4M2016 | 4.4M2025 | +2.9%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
HBIO assets
HBIO liabilities and equity
HBIO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
HBIO balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $8.6M | $4.1M | $4.3M | $4.5M | $7.8M | $8.3M | $8.3M | $8.2M | $5.7M | $5.6M |
| Cash & equivalents | $8.6M | $4.1M | $4.3M | $4.5M | $7.8M | $8.3M | $8.3M | $8.2M | $5.7M | $5.6M |
| Short-term investments | — | — | — | — | — | — | — | — | $0 | $0 |
| Receivables | $16.0M | $14.9M | $16.1M | $16.7M | $21.8M | $17.8M | $20.7M | $21.5M | $17.1M | $19.9M |
| Inventory | $20.8M | $23.2M | $24.7M | $26.4M | $27.6M | $22.3M | $22.1M | $25.1M | $21.4M | $20.0M |
| Other current assets | $2.8M | $2.9M | $3.9M | $3.5M | $4.3M | $3.4M | $2.5M | $0 | $3.4M | $0 |
| Total current assets | $48.2M | $45.1M | $49.0M | $51.1M | $61.6M | $51.7M | $53.6M | $54.7M | $47.5M | $45.5M |
| Property, plant & equipment (net) | $4.8M | $11.2M | $8.8M | $9.2M | $10.3M | $11.7M | $13.2M | $5.9M | $4.1M | $4.3M |
| Goodwill & intangible assets | $17.2M | $67.5M | $73.1M | $77.3M | $85.1M | $91.7M | $95.8M | $103.1M | $57.2M | $56.7M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $37,000 | $0 |
| Other non-current assets | $9.9M | $2.8M | $6.5M | $7.8M | $5.4M | $1.1M | $2.3M | $4.4M | $469,000 | $1.3M |
| Total assets | $80.1M | $126.6M | $137.4M | $145.4M | $162.3M | $156.3M | $164.9M | $168.1M | $109.4M | $107.8M |
| Liabilities | ||||||||||
| Accounts payable | $3.7M | $4.8M | $5.6M | $6.4M | $4.9M | $6.0M | $5.3M | $7.4M | $4.4M | $6.2M |
| Short-term debt | $1.5M | $38.1M | $7.3M | $5.9M | $5.4M | $3.8M | $9.3M | $2.0M | $2.8M | $2.4M |
| Deferred revenue | $4.8M | $3.8M | $4.5M | $3.4M | $4.3M | $3.8M | $3.9M | $4.2M | $633,000 | $500,000 |
| Total current liabilities | $22.0M | $55.0M | $26.5M | $23.2M | $25.3M | $21.1M | $25.3M | $21.5M | $14.0M | $14.6M |
| Long-term debt | $35.9M | $0 | $30.7M | $43.0M | $45.1M | $46.3M | $46.9M | $58.8M | $9.0M | $11.4M |
| Lease obligations | $8.4M | $7.5M | $6.2M | $7.4M | $8.6M | $9.6M | $10.6M | — | — | — |
| Other long-term liabilities | $8.5M | $8.3M | $7.0M | $6.9M | $8.5M | $12.2M | $10.9M | $5.6M | $5.4M | $9.6M |
| Total liabilities | $66.3M | $63.3M | $64.3M | $73.1M | $78.9M | $79.6M | $83.2M | $85.9M | $28.5M | $35.6M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $447,000 | $441,000 | $434,000 | $454,000 | $452,000 | $444,000 | $438,000 | $436,000 | $419,000 | $418,000 |
| Retained earnings (deficit) | −$214.7M | −$158.0M | −$145.6M | −$142.2M | −$132.7M | −$132.4M | −$124.6M | −$119.9M | −$117.0M | −$116.0M |
| Treasury stock | — | — | — | — | — | −$10.7M | −$10.7M | −$10.7M | −$10.7M | −$10.7M |
| Accumulated other comprehensive income | −$11.7M | −$15.7M | −$14.2M | −$15.1M | −$10.0M | −$13.1M | −$12.7M | −$13.5M | −$10.7M | −$16.7M |
| Minority interest | — | — | — | — | — | — | — | — | $0 | $0 |
| Total shareholders' equity | $13.7M | $63.3M | $73.1M | $72.2M | $83.4M | $76.7M | $81.7M | $82.2M | $80.9M | $72.2M |
| Key figures | ||||||||||
| Total debt | $44.3M | $44.5M | $42.8M | $54.2M | $57.0M | $57.6M | $64.5M | $60.8M | $11.7M | $13.7M |
| Net cash (debt) | −$35.7M | −$40.4M | −$38.5M | −$49.7M | −$49.1M | −$49.3M | −$56.1M | −$52.6M | −$6.0M | −$8.2M |
| Working capital | $26.3M | −$9.8M | $22.5M | $27.9M | $36.3M | $30.6M | $28.3M | $33.2M | $33.5M | $30.9M |
| Tangible book value | −$3.5M | −$4.1M | −$27,000 | −$5.1M | −$1.7M | −$15.1M | −$14.1M | −$20.9M | $23.7M | $15.5M |
| Book value per share | $3.09 | $14.55 | $17.23 | $17.44 | $20.67 | $19.84 | $21.60 | $22.55 | $23.28 | $21.10 |
| Shares outstanding | 4.4M | 4.4M | 4.2M | 4.1M | 4.0M | 3.9M | 3.8M | 3.6M | 3.5M | 3.4M |
| Current ratio | 2.20 | 0.82 | 1.85 | 2.20 | 2.43 | 2.46 | 2.12 | 2.54 | 3.39 | 3.11 |
| Quick ratio | 1.12 | 0.35 | 0.77 | 0.91 | 1.17 | 1.24 | 1.15 | 1.38 | 1.63 | 1.75 |
| Debt / equity | 3.22 | 0.70 | 0.59 | 0.75 | 0.68 | 0.75 | 0.79 | 0.74 | 0.15 | 0.19 |
| Equity / assets | 17.2% | 50.0% | 53.2% | 49.7% | 51.4% | 49.1% | 49.6% | 48.9% | 74.0% | 67.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $6.5M | $7.1M | $8.6M | $6.8M | $7.4M | $5.5M | $4.1M | $4.6M | $4.0M | $4.3M | $4.3M | $5.3M |
| Cash & equivalents | $6.5M | $7.1M | $8.6M | $6.8M | $7.4M | $5.5M | $4.1M | $4.6M | $4.0M | $4.3M | $4.3M | $5.3M |
| Receivables | $14.5M | $14.6M | $16.0M | $12.1M | $11.9M | $13.5M | $14.9M | $12.8M | $12.5M | $15.3M | $16.1M | $15.0M |
| Inventory | $22.2M | $22.2M | $20.8M | $21.6M | $22.3M | $22.8M | $23.2M | $26.0M | $25.1M | $24.1M | $24.7M | $25.8M |
| Other current assets | $3.2M | $3.6M | $2.8M | $3.3M | $3.3M | $3.1M | $2.9M | $3.4M | $4.8M | $4.4M | $3.9M | $4.3M |
| Total current assets | $46.5M | $47.5M | $48.2M | $43.8M | $45.0M | $44.9M | $45.1M | $46.8M | $46.4M | $48.1M | $49.0M | $50.5M |
| Property, plant & equipment (net) | $11.7M | $11.6M | $4.8M | $12.5M | $12.0M | $12.3M | $11.2M | $11.7M | $9.2M | $8.9M | $8.8M | $8.4M |
| Goodwill & intangible assets | $15.6M | $16.3M | $17.2M | $17.9M | $19.3M | $19.1M | $67.5M | $69.8M | $70.1M | $71.4M | $73.1M | $73.3M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $2.5M | $2.6M | $9.9M | $3.8M | $3.8M | $3.5M | $2.8M | $2.9M | $3.2M | $4.8M | $6.5M | $7.5M |
| Total assets | $76.3M | $77.9M | $80.1M | $78.0M | $80.1M | $79.8M | $126.6M | $131.2M | $128.9M | $133.2M | $137.4M | $139.7M |
| Liabilities | ||||||||||||
| Accounts payable | $6.2M | $5.3M | $3.7M | $5.2M | $4.7M | $4.8M | $4.8M | $5.3M | $5.7M | $6.0M | $5.6M | $6.3M |
| Short-term debt | $1.6M | $1.6M | $1.5M | $35.5M | $36.3M | $37.4M | $38.1M | $4.7M | $4.8M | $4.9M | $7.3M | $5.6M |
| Deferred revenue | $3.6M | $5.0M | $4.8M | $4.1M | $3.1M | $3.4M | $3.8M | $3.7M | $4.0M | $4.4M | $7.7M | $4.0M |
| Total current liabilities | $24.8M | $23.9M | $22.0M | $54.4M | $55.2M | $55.6M | $55.0M | $22.8M | $22.6M | $25.7M | $26.5M | $24.2M |
| Long-term debt | $36.7M | $36.2M | $35.9M | $0 | $0 | $0 | $0 | $34.3M | $32.0M | $31.9M | $30.7M | $35.3M |
| Lease obligations | $7.5M | $7.9M | $8.4M | $8.8M | $8.4M | $8.6M | $7.5M | $7.8M | $5.8M | $5.8M | $6.2M | $6.5M |
| Other long-term liabilities | $7.4M | $7.8M | $8.5M | $9.5M | $9.2M | $9.4M | $8.3M | $8.9M | $7.1M | $6.8M | $7.0M | $6.0M |
| Total liabilities | $68.9M | $67.9M | $66.3M | $63.9M | $64.4M | $65.0M | $63.3M | $65.9M | $61.7M | $64.3M | $64.3M | $65.4M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $447,000 | $447,000 | $447,000 | $446,000 | $445,000 | $442,000 | $441,000 | $436,000 | $436,000 | $434,000 | $434,000 | $457,000 |
| Retained earnings (deficit) | −$221.0M | −$218.1M | −$214.7M | −$211.9M | −$210.6M | −$208.3M | −$158.0M | −$158.0M | −$153.2M | −$150.3M | −$145.6M | −$143.8M |
| Accumulated other comprehensive income | −$12.4M | −$12.3M | −$11.7M | −$12.4M | −$11.7M | −$14.4M | −$15.7M | −$13.1M | −$14.9M | −$14.8M | −$14.2M | −$15.3M |
| Total shareholders' equity | $7.4M | $10.0M | $13.7M | $14.1M | $15.7M | $14.8M | $63.3M | $65.3M | $67.2M | $68.8M | $73.1M | $74.3M |
| Key figures | ||||||||||||
| Total debt | $44.2M | $44.1M | $44.3M | $42.8M | $43.3M | $44.6M | $44.5M | $45.7M | $41.5M | $41.4M | $42.8M | $45.3M |
| Net cash (debt) | −$37.7M | −$37.0M | −$35.7M | −$36.0M | −$35.9M | −$39.1M | −$40.4M | −$41.1M | −$37.4M | −$37.1M | −$38.5M | −$39.9M |
| Working capital | $21.7M | $23.6M | $26.3M | −$10.6M | −$10.2M | −$10.7M | −$9.8M | $24.0M | $23.8M | $22.5M | $22.5M | $26.3M |
| Tangible book value | −$8.1M | −$6.2M | −$3.5M | −$3.8M | −$3.6M | −$4.3M | −$4.1M | −$4.5M | −$2.8M | −$2.6M | −$27,000 | $969,000 |
| Book value per share | $1.64 | $2.25 | $3.09 | $3.16 | $3.55 | $3.36 | $14.55 | $14.98 | $15.46 | $15.85 | $17.11 | $17.40 |
| Shares outstanding | 4.5M | 4.5M | 4.4M | 4.5M | 4.4M | 4.4M | 4.4M | 4.4M | 4.3M | 4.3M | 4.3M | 4.3M |
| Current ratio | 1.87 | 1.99 | 2.20 | 0.81 | 0.81 | 0.81 | 0.82 | 2.06 | 2.05 | 1.88 | 1.85 | 2.09 |
| Quick ratio | 0.85 | 0.91 | 1.12 | 0.35 | 0.35 | 0.34 | 0.35 | 0.76 | 0.73 | 0.76 | 0.77 | 0.84 |
| Debt / equity | 5.96 | 4.39 | 3.22 | 3.04 | 2.75 | 3.01 | 0.70 | 0.70 | 0.62 | 0.60 | 0.59 | 0.61 |
| Equity / assets | 9.7% | 12.9% | 17.2% | 18.0% | 19.6% | 18.6% | 50.0% | 49.8% | 52.2% | 51.7% | 53.2% | 53.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 13, 2026); data from EODHD.
HBIO financial position
At the end of fiscal 2025 (December 31, 2025), Harvard Bioscience had total assets of $80.1 million (down 36.8% from a year earlier), total liabilities of $66.3 million and shareholders' equity of $13.7 million. It held $8.6 million in cash and short-term investments against $44.3 million of debt, net debt of $35.7 million. Its current ratio was 2.20. In the latest quarter (ended June 30, 2026) total assets were $76.3 million and equity $7.4 million.
Related: HBIO income statement, HBIO cash flow statement, HBIO key metrics. See the HBIO stock overview for the latest quote and news.
HBIO balance sheet FAQ
What are Harvard Bioscience's total assets?
Harvard Bioscience reported total assets of $80.1 million at the end of fiscal 2025 (December 31, 2025), compared with $126.6 million a year earlier.
How much debt does Harvard Bioscience have?
Harvard Bioscience had $44.3 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 3.22.
How much cash does Harvard Bioscience have?
Harvard Bioscience held $8.6 million in cash and short-term investments at the end of fiscal 2025; with $44.3 million of debt that is net debt of $35.7 million.
What is Harvard Bioscience's book value?
Harvard Bioscience's shareholders' equity (book value) was $13.7 million at the end of fiscal 2025, or $3.09 per share.
What is Harvard Bioscience's current ratio?
Harvard Bioscience had current assets of $48.2 million and current liabilities of $22.0 million, a current ratio of 2.20 (it can cover its short-term obligations).
How much goodwill does Harvard Bioscience have?
Harvard Bioscience carried $17.2 million of goodwill and intangible assets, 21.5% of total assets, at the end of fiscal 2025.